[Simultaneous development of a bronchial cancer and a pulmonary tuberculosis: difficulty of the diagnosis].

F. Patte,M. Bertin,G. Geauchant

1972-12-10

Abstract:

What problem does this paper attempt to address?

Metabolomic Analysis of N-acetylcysteine Protection of Injury from Gadolinium-DTPA Contrast Agent in Rats with Chronic Renal Failure

Chuanling Wan,Rong Xue,Youyang Zhan,Yijie Wu,Xiaojing Li,Fengkui Pei

DOI: https://doi.org/10.1089/omi.2017.0114

2017-01-01

OMICS A Journal of Integrative Biology

Abstract:Gadolinium-based contrast agents (GBCAs) are frequently used to enhance the diagnostic efficacy of magnetic resonance imaging. On the other hand, the association between GBCA administration in patients with advanced renal disease and nephrogenic systemic fibrosis (NSF) was also noted. NSF is a systemic disorder characterized by widespread tissue fibrosis that may lead to death. N-acetylcysteine (NAC) protects rats from injury induced by gadolinium-based contrast agents, but the underlying mechanisms remain unclear. In this study, a nuclear magnetic resonance-based metabolomic approach was used to systematically investigate the protective effects of NAC on Gd-DTPA-induced injury. Thirty-two male Sprague-Dawley rats were given adenine (200 mg·kg-1 body weight) by oral gavage once a day for 3 weeks to induce chronic renal failure (CRF). NAC (600 mg/L in drinking water for 9 days) pretreatment was initiated 2 days before Gd-DTPA injection (a single tail vein injection, 2 mmol/kg body weight). Serum and liver samples were collected on day 7 after Gd-DTPA injection. By study design, the serum and hepatic metabolic changes of rats were measured in four groups of eight each: CRF, CRF-Gd, CRF-Gd-NAC, and CRF-NAC. Gd-DTPA administration to rats with CRF resulted in disturbances of several metabolic pathways, including glucose, lipid, glutamate, choline, gut microbiota, one-carbon, and purine metabolism. NAC pretreatment reversed the abundance changes of high-density lipoprotein, low-density lipoprotein, very low-density lipoprotein, glutamate, glutamine, oxidized glutathione, choline, phosphocholine, glycerophosphocholine, trimethylamine, and trimethylamine-N-oxide induced by Gd-DTPA. It is noteworthy, however, that the ameliorating effects of NAC on the disturbance of glutamate, choline, and gut microbiota metabolism may be specific to Gd-DTPA. In all, these findings could be potentially useful to decipher the underlying mechanisms of NAC protective effects from the injury induced by gadolinium-based contrast agents.
Gadolinium-based contrast agents – what is the evidence for ‘gadolinium deposition disease’ and the use of chelation therapy?

Kerry A. Layne,David M. Wood,Paul I. Dargan

DOI: https://doi.org/10.1080/15563650.2019.1681442

2019-10-30

Clinical Toxicology

Abstract:Introduction: Gadolinium-based contrast agents are widely used for magnetic resonance imaging and, until recently, had been generally considered to have an excellent safety profile in patients with normal renal function. Nephrogenic systemic fibrosis is a well-established disease process involving fibrosis of the skin and internal organs seen in some patients with severely impaired renal function following exposure to these agents. Following reports that individuals with normal renal function may experience gadolinium deposition within brain and bone tissue, the term "gadolinium deposition disease" has been proposed and the use of chelating agents has been recommended to treat this "disease".Objectives: This review will address the clinical evidence for "gadolinium deposition disease" and discuss whether chelation therapy is appropriate for individuals who believe they have this condition.Methods: Electronic databases (PUBMED, Ovid MEDLINE and EMBASE) were searched up to 1st October 2019 for all studies evaluating clinical signs or symptoms related to potential gadolinium toxicity post-gadolinium-based contrast agent exposure in subjects with normal renal function, or papers evaluating the potential chelation of gadolinium in humans.Does "gadolinium deposition disease" exist as a novel condition? We identified four clinical studies relating to "gadolinium deposition disease", including one that included some discussion of the use of chelation therapy. Two of the clinical studies presented data from anonymous online surveys that recruited participants from support forums for people who self-identified as having gadolinium-based contrast agent–induced toxicity, with questions focussing on their reported symptoms and signs. The published literature to date has demonstrated that gadolinium deposition within the brain primarily occurs within the dentate nucleus and globus pallidus. These patients did not complain of movement disorders, but instead reported generalised sensory symptoms, which would not be expected to occur with pathology in these areas of the brain. There was considerable selection bias and a lack of available clinical information to exclude alternative medical diagnoses for these series, thus rendering the results difficult to interpret.Role of chelation therapy in patients exposed to gadolinium-based contrast agent: One study reported data from 25 patients who were diagnosed with "gadolinium deposition disease" according to unspecified criteria and were treated with intravenous calcium or zinc trisodium pentetate. The authors reported an increase in urine gadolinium concentrations following administration of the chelating agents, which they attributed to re-chelation of gadolinium from tissue deposits, however, there are insufficient data to be able to substantiate this.Conclusion: There is currently no published information from well-designed clinical studies that support a link between gadolinium deposition and the development of clinical sequelae in patients with normal renal function. Clinicians should exercise caution when considering whether or not gadolinium is of relevance in patients reporting symptoms after administration of gadolinium-based contrast agents. The inappropriate use of chelation therapy in patients with no clear evidence-based indication for their use potentially increases the risk of clinically significant harm to these patients from the adverse effects of chelation. Further research and well-designed clinical and epidemiological surveillance is needed to determine whether there are toxicological risks related to gadolinium exposure from the use of gadolinium-based contrast agents in patients with normal renal function.

toxicology
Benefits and Detriments of Gadolinium from Medical Advances to Health and Ecological Risks

Colin Unruh,Nicolas Van Bavel,Max Anikovskiy,Elmar J. Prenner

DOI: https://doi.org/10.3390/molecules25235762

IF: 4.6

2020-12-07

Molecules

Abstract:Gadolinium (Gd)-containing chelates have been established as diagnostics tools. However, extensive use in magnetic resonance imaging has led to increased Gd levels in industrialized parts of the world, adding to natural occurrence and causing environmental and health concerns. A vast amount of data shows that metal may accumulate in the human body and its deposition has been detected in organs such as brain and liver. Moreover, the disease nephrogenic systemic fibrosis has been linked to increased Gd3+ levels. Investigation of Gd3+ effects at the cellular and molecular levels mostly revolves around calcium-dependent proteins, since Gd3+ competes with calcium due to their similar size; other reports focus on interaction of Gd3+ with nucleic acids and carbohydrates. However, little is known about Gd3+ effects on membranes; yet some results suggest that Gd3+ interacts strongly with biologically-relevant lipids (e.g., brain membrane constituents) and causes serious structural changes including enhanced membrane rigidity and propensity for lipid fusion and aggregation at much lower concentrations than other ions, both toxic and essential. This review surveys the impact of the anthropogenic use of Gd emphasizing health risks and discussing debilitating effects of Gd3+ on cell membrane organization that may lead to deleterious health consequences.

chemistry, multidisciplinary,biochemistry & molecular biology
Biochemical Effects of Gadolinium Chloride in Rats Liver and Kidney Studied by 1H NMR Metabolomics

Liao Peiqiu,Wei Lai,Wu Huifeng,Li Weisheng,Wu Yijie,Li Xiaojing,Ni Jiazuan,Pei Fengkui

DOI: https://doi.org/10.1016/s1002-0721(08)60234-3

IF: 4.632

2009-01-01

Journal of Rare Earths

Abstract:The biochemical effects of gadolinium chloride were studied using high-resolution 1H nuclear magnetic resonance (NMR) spectroscopy to investigate the biochemical composition of tissue (liver and kidney) aqueous extracts obtained from control and gadolinium chloride (GdCl3) (10 and 50 mg/kg body weight, intraperitoneal injection, i.p.) treated rats. Tissue samples were collected at 48, 96 and 168 h p.d. after exposure to GdCl3, and extracted using methanol/chloroform solvent system. 1H NMR spectra of tissue extracts were analyzed by pattern recognition using principal components analysis. The liver damages caused by GdCl3 were characterized by increased succinate and decreased glycogen level and elevated lactate, alanine and betaine concentration in liver. Furthermore, the increase of creatine and lactate, and decrease of glutamate, alanine, phosphocholine, glycophosphocholine (GPC), betaine, myo-inositol and trimethylamine N-oxide (TMAO) levels in kidney illustrated kidney disturbance induced by GdCl3.
Toxicity of MRI and CT contrast agents

Kendra M Hasebroock,Natalie J Serkova

DOI: https://doi.org/10.1517/17425250902873796

2009-04-01

Abstract:Anatomical and physiological imaging using CT and MRI are playing a critical role in patients' diagnosis, disease characterization and treatment planning. CT- and MRI-based protocols increasingly require an injection of iodinated CT and gadolinium (Gd)-based MRI contrast media. Although routinely used in clinical practice, iodinated and to a less extent Gd-based contrast media possess side effects: life-threatening contrast-induced nephropathy (CIN) is associated with CT and nephrogenic systemic fibrosis (NSF) with MRI contrast agents. CIN is defined as an acute decline in renal functions (serum creatinine increase > 0.5 mg/dl) after administration of iodinated contrast media. Patients with moderate-to-severe chronic kidney disease are considered the highest risk group for development of CIN. CIN is more common with ionic high-osmolar contrast CT media. NSF is a rare condition characterized by the formation of connective tissue in the skin and systemically in the lung, liver, heart and kidney. Patients with end stage kidney disease, acute kidney injury and stage 4-5 chronic kidney disease are at a high risk for NSF. The nonionic linear Gd-chelates are associated with the highest risk of NSF. This review summarizes the incidence, symptoms, safety profile of various CT and MRI contrast agents based on their physiochemical properties.

pharmacology & pharmacy,biochemistry & molecular biology,toxicology
Toxicity Mechanisms of Gadolinium and Gadolinium-Based Contrast Agents—A Review

Susana Coimbra,Susana Rocha,Nícia Reis Sousa,Cristina Catarino,Luís Belo,Elsa Bronze-da-Rocha,Maria João Valente,Alice Santos-Silva

DOI: https://doi.org/10.3390/ijms25074071

IF: 5.6

2024-04-06

International Journal of Molecular Sciences

Abstract:Gadolinium-based contrast agents (GBCAs) have been used for more than 30 years to improve magnetic resonance imaging, a crucial tool for medical diagnosis and treatment monitoring across multiple clinical settings. Studies have shown that exposure to GBCAs is associated with gadolinium release and tissue deposition that may cause short- and long-term toxicity in several organs, including the kidney, the main excretion organ of most GBCAs. Considering the increasing prevalence of chronic kidney disease worldwide and that most of the complications following GBCA exposure are associated with renal dysfunction, the mechanisms underlying GBCA toxicity, especially renal toxicity, are particularly important. A better understanding of the gadolinium mechanisms of toxicity may contribute to clarify the safety and/or potential risks associated with the use of GBCAs. In this work, a review of the recent literature concerning gadolinium and GBCA mechanisms of toxicity was performed.

biochemistry & molecular biology,chemistry, multidisciplinary
Gadolinium Deposition in the Liver and Brain in a Rat Model with Liver Fibrosis after Intravenous Administration of Gadoxetate Disodium

Peiying Wei,Qiuhui Hu,Chengbin He,Peng Hua,Di Yang,Chang Shao,Lesi Xie,Zhijiang Han,Xiaoxuan Zhou,Zhongxiang Ding,Hongjie Hu

DOI: https://doi.org/10.1016/j.heliyon.2024.e27419

IF: 3.776

2024-01-01

Heliyon

Abstract:Objectives: To investigate gadolinium deposition in the liver and brain in a rat model with liver fibrosis (LF) after intravenous administration of gadoxetate disodium (GD) and the histological effects of gadolinium deposition in the liver and brain. Methods: Adult male Sprague -Dawley rats were randomly assigned to one of the three groups: 1) LF group received intraperitoneal injection of carbon tetrachloride (CCl 4 ) for 9 weeks alone; 2) LF &GD group received CCl 4 and intravenous administration of GD (for 5 consecutive days); 3) GD group received olive oil and GD. Seven days after the final injection of GD, the deep cerebellar nuclei (DCN) and liver were excised to determine gadolinium concentrations via inductively coupled plasma mass spectrometry, and histologic staining was performed. Bonferroni 's post-hoc test and Wilcoxon rank sum test were used to compare the differences between the three groups. Results: The concentrations of retained gadolinium in the liver in the LF &GD group (2.18 +/- 0.44 mu g/g) were significantly greater compared to the LF group (0.02 +/- 0.01 mu g/g, P < 0.001) and GD group (0.37 +/- 0.11 g/g, P < 0.001). Also, the concentrations of retained gadolinium in DCN were increased in the LF &GD group (0.13 +/- 0.06 g/g) compared to the LF group (0.01 +/- 0.00 mu g/g, P < 0.001) and GD group (0.06 +/- 0.02 g/g, P = 0.019). No histopathological alterations were detected in the liver and DCN between LF &GD group and LF group. Conclusions: LF aggravated gadolinium deposition in the liver and DCN after administration of GD. However, no significant acute histological alterations were observed due to gadolinium deposition.
Gadolinium‐based Contrast Agents for Magnetic Resonance Cancer Imaging

Zhuxian Zhou,Zheng‐Rong Lu

DOI: https://doi.org/10.1002/wnan.1198

2012-01-01

Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology

Abstract:AbstractMagnetic resonance imaging (MRI) is a clinical imaging modality effective for anatomical and functional imaging of diseased soft tissues, including solid tumors. MRI contrast agents (CA) have been routinely used for detecting tumor at an early stage. Gadolinium‐based CA are the most commonly used CA in clinical MRI. There have been significant efforts to design and develop novel Gd(III) CA with high relaxivity, low toxicity, and specific tumor binding. The relaxivity of the Gd(III) CA can be increased by proper chemical modification. The toxicity of Gd(III) CA can be reduced by increasing the agents' thermodynamic and kinetic stability, as well as optimizing their pharmacokinetic properties. The increasing knowledge in the field of cancer genomics and biology provides an opportunity for designing tumor‐specific CA. Various new Gd(III) chelates have been designed and evaluated in animal models for more effective cancer MRI. This review outlines the design and development, physicochemical properties, and in vivo properties of several classes of Gd(III)‐based MR CA tumor imaging. WIREs Nanomed Nanobiotechnol 2013, 5:1–18. doi: 10.1002/wnan.1198This article is categorized under: Diagnostic Tools > Biosensing Diagnostic Tools > In Vivo Nanodiagnostics and Imaging
Contrast Media-driven Anthropogenic Gadolinium: Knowns and Unknowns

Robert E Lenkinski,Neil M Rofsky

DOI: https://doi.org/10.1148/radiol.240020

IF: 19.7

2024-04-24

Radiology

Abstract:Gadolinium-based contrast agents (GBCAs) have augmented the capabilities of MRI, which has led to their widespread and increasing use in radiology practice. GBCAs are introduced into the environment through disposal of unused product and elimination after intravenous injection, both primarily via liquid dispersion into the environment. This human introduction of gadolinium into the environment, referred to as anthropogenic gadolinium, is associated with the detection of gadolinium in water...

radiology, nuclear medicine & medical imaging
Parallel Comparative Studies on Mouse Toxicity of Oxide Nanoparticle- and Gadolinium-Based T1 MRI Contrast Agents

Rui Chen,Daishun Ling,Lin Zhao,Shuaifei Wang,Ying Liu,Ru Bai,Seungmin Baik,Yuliang Zhao,Chunying Chen,Taeghwan Hyeon

DOI: https://doi.org/10.1021/acsnano.5b05783

IF: 17.1

2015-01-01

ACS Nano

Abstract:Magnetic resonance imaging (MRI) contrast agents with high relaxivity are highly desirable because they can significantly increase the accuracy of diagnosis. However, they can be potentially toxic to the patients. In this study, using a mouse model, we investigate the toxic effects and subsequent tissue damage induced by three T1 MRI contrast agents: gadopentetate dimeglumine injection (GDI), a clinically used gadolinium (Gd)-based contrast agent (GBCAs), and oxide nanoparticle (NP)-based contrast agents, extremely small-sized iron oxide NPs (ESIONs) and manganese oxide (MnO) NPs. Biodistribution, hematological and histopathological changes, inflammation, and the endoplasmic reticulum (ER) stress responses are evaluated for 24 h after intravenous injection. These thorough assessments of the toxic and stress responses of these agents provide a panoramic description of safety concerns and underlying mechanisms of the toxicity of contrast agents in the body. We demonstrate that ESIONs exhibit fewer adverse effects than the MnO NPs and the clinically used GDI GBCAs, providing useful information on future applications of ESIONs as potentially safe MRI contrast agents.
Toxicological Risk Assessments of Iron Oxide Nanocluster- and Gadolinium-Based T1MRI Contrast Agents in Renal Failure Rats

Qinjie Weng,Xi Hu,Jiahuan Zheng,Fan Xia,Nan Wang,Hongwei Liao,Ying Liu,Dokyoon Kim,Jianan Liu,Fangyuan Li,Qiaojun He,Bo Yang,Chunying Chen,Taeghwan Hyeon,Daishun Ling

DOI: https://doi.org/10.1021/acsnano.9b01511

IF: 17.1

2019-01-01

ACS Nano

Abstract:Gadolinium-based contrast agents (GBCAs) are widely used for T1-weighted magnetic resonance imaging (MRI) in clinic diagnosis. However, a major drawback of GBCAs is that they can increase the toxicological risk of nephrogenic systemic fibrosis (NSF) in patients with advanced renal dysfunction. Hence, safer alternatives to GBCAs are currently in demand, especially for patients with renal diseases. Here we investigated the potential of polyethylene glycol (PEG)-stabilized iron oxide nanoclusters (IONCs) as biocompatible T1MRI contrast agents and systematically evaluated their NSF-related risk in rats with renal failure. We profiled the distribution, excretion, histopathological alterations, and fibrotic gene expressions after administration of IONCs and GBCAs. Our results showed that, compared with GBCAs, IONCs exhibited dramatically improved biosafety and a much lower risk of causing NSF, suggesting the feasibility of substituting GBCAs with IONCs in clinical MRI diagnosis of patients with renal diseases.
Epidural anesthesia in a patient with hyperkalemic periodic paralysis undergoing orthopedic surgery

R. Aouad,P. Atanassoff

DOI: https://doi.org/10.1007/BF03018562

Abstract:
MRI Gadolinium‐Based Contrast Media: Meeting Radiological, Clinical, and Environmental Needs

Martin Bendszus,Andrea Laghi,Josep Munuera,Lawrence N. Tanenbaum,Bachir Taouli,Harriet C. Thoeny

DOI: https://doi.org/10.1002/jmri.29181

IF: 4.4

2024-01-17

Journal of Magnetic Resonance Imaging

Abstract:Gadolinium‐based contrast agents (GBCAs) are routinely used in magnetic resonance imaging (MRI). They are essential for choosing the most appropriate medical or surgical strategy for patients with serious pathologies, particularly in oncologic, inflammatory, and cardiovascular diseases. However, GBCAs have been associated with an increased risk of nephrogenic systemic fibrosis in patients with renal failure, as well as the possibility of deposition in the brain, bones, and other organs, even in patients with normal renal function. Research is underway to reduce the quantity of gadolinium injected, without compromising image quality and diagnosis. The next generation of GBCAs will enable a reduction in the gadolinium dose administered. Gadopiclenol is the first of this new generation of GBCAs, with high relaxivity, thus having the potential to reduce the gadolinium dose while maintaining good in vivo stability due to its macrocyclic structure. High‐stability and high‐relaxivity GBCAs will be one of the solutions for reducing the dose of gadolinium to be administered in clinical practice, while the development of new technologies, including optimization of MRI acquisitions, new contrast mechanisms, and artificial intelligence may help reduce the need for GBCAs. Future solutions may involve a combination of next‐generation GBCAs and image‐processing techniques to optimize diagnosis and treatment planning while minimizing exposure to gadolinium. Level of Evidence 5 Technical Efficacy Stage 3

radiology, nuclear medicine & medical imaging
Carbohydrate craving. Relationship between carbohydrate intake and disorders of mood.

J. Wurtman

Drugs

Abstract:Common to repetitive episodes of weight gain or failures to succeed on weight loss regimens is the excessive consumption of carbohydrate-rich foods in association with dysphoria. The brain neurotransmitter, serotonin, seems to be involved in the abnormal regulation of mood and food intake that underlies diet failures or weight gain in individuals who suffer from carbohydrate craving obesity (CCO), premenstrual syndrome (PMS) and seasonal affective disorder (SAD). All 3 syndromes are characterized by episodic bouts of increased carbohydrate consumption and depressed mood. Studies with dietary treatment or drugs that enhance serotoninergic neurotransmission have found that increased serotonin neurotransmission is associated with normalised food intake and mood. These results suggest that periodic intervention with dietary or drug treatment that increases serotonin availability may help sustain weight or assist in weight loss.
A Contrast Examination of Proinflammatory Effects on Kidney Function for γ-Fe2O3 NP and Gadolinium Dimeglumine

Qian Xie,Tao Wen,Aiyun Yang,Xue Zhang,Bo Chen,Jie Meng,Jian Liu,Ning Gu,Haiyan Xu

DOI: https://doi.org/10.2147/IJN.S299004

2021-03-18

Abstract:Background: Contrast-enhanced magnetic resonance imaging (MRI) is a powerful diagnostic tool for many diseases. In many situations, the contrasts are repeatedly administrated in order to monitor and assess the disease progression. Objective: To investigate and compare the biological effects of γ-Fe2O3 nanoparticle (NP) and gadolinium dimeglumine (Gd-DTPA) with high and multiple doses on the kidney of healthy mice. Methods: Polydextrose sorbitol carboxymethyl ether coated γ-Fe2O3 NP with hydrodynamic size of 68.2 nm and clinically applied Gd-DTPA were employed on healthy mice with the repeatedly intravenous administration of high doses. The cell viability of human umbilical vein endothelial cells (HUVEC) in high doses of these two contrast agents were measured using the xCELLigence Real-Time Cell Analysis (RTCA) S16 Instrument. The biological effects of γ-Fe2O3 NP and Gd-DTPA on the kidney were obtained using a biochemical automatic analyzer and multiple proinflammatory factor kit on the serum. Histopathological and immunohistochemistry analysis were taken on kidney tissues. Results: It showed that the proinflammatory responses elicited by the γ-Fe2O3 NPs were weaker than that by Gd-DTPA, evidenced by the relatively much lower level of IL-1β, IL-6, IL-18, TNF-α, C-reactive protein (CRP) and Ferritin. At the same time, the γ-Fe2O3 NPs did not have the biochemical index elevated, while the Gd-DTPA did. Conclusion: The γ-Fe2O3 NPs induced weaker proinflammatory effects in reference to the Gd-DTPA, indicating better renal safety. Therefore, it is suggested that γ-Fe2O3 NPs should be safer and optional choice when repeated contrast-enhanced MRI is necessary.
Deposition of Gadolinium in the Central and Peripheral Nervous Systems and Its Effects on Sensory, Cognitive, and Athletic Implications after Multiple Injections of Gadolinium-Based Contrast Agents in Rats

Xiang Yao,Jingyi Hu,Guangsong Wang,Xiaoning Lin,Jin Sun,Guijiang Dong,Junlong Kang,Wei Feng,Bowen Xie,Yanlin Huang,Xinhua Tian,E Chen

DOI: https://doi.org/10.3174/ajnr.A8295

2024-08-09

Abstract:Background and purpose: After repeat administration of gadolinium-based contrast agents (GBCAs), the association between gadolinium retention in the central and peripheral nervous systems and the main manifestations of myelopathy and progressive neurologic symptoms remains unclear. We investigated the effects of the repeat administration of GBCAs on gadolinium retention in the central and peripheral nervous systems and the sensory, cognitive, and athletic implications. Materials and methods: Forty-eight male Wistar rats (6 weeks of age) were randomly divided into 4 experimental groups (12 rats in each group): the gadodiamide group (linear and nonionic GBCAs), the gadopentetate dimeglumine group (linear and ionic GBCAs), the gadoterate meglumine group (macrocyclic and ionic GBCAs), and the control group (0.9% saline solution). The brains of the rats were scanned using 9.4T MRI. Sensory behavioral tests were performed to assess the effect of GBCAs on pain sensitivity function. Gadolinium deposition in the brain, spinal cord, and peripheral nerves was determined by inductively coupled plasma mass-spectrometry. Transmission electron microscopy was used to observe the microscopic distribution of gadolinium after deposition in the spinal cord. The histopathologic features in the spinal cord were analyzed by H&E staining, Nissl staining, glial fibrillary acidic protein staining, and neuron-specific enolase staining after administration of GBCAs. Results: All GBCAs resulted in gadolinium deposition in the central and peripheral nerve tissues, with the highest deposition in the sciatic nerve tissue (mean, 62.86 [SD, 12.56] nmol/g). Decreased muscle power, impairment of spatial cognitive function power, and pain hypersensitivity to thermal and mechanical stimuli were observed after exposure to gadodiamide. At the spinal cord, transmission electron microscopy found that the region of gadolinium depositions had a spheric structure similar to "sea urchins" and was mainly located near the vascular basement membrane. Conclusions: Multiple injections of GBCAs caused gadolinium deposition in the brain, spinal cord, and peripheral nerves, especially in the spinal cords of the gadodiamide group. Gadodiamide led to pain hypersensitivity and decreased muscle power and cognitive ability. For the patients who are hypersensitive to pain and need multiple MRI examinations, we recommend using macrocyclic GBCAs and the lowest dose possible.
Comprehensive Analysis of the Spatial Distribution of Gadolinium, Iron, Manganese, and Phosphorus in the Brain of Healthy Rats After High-Dose Administrations of Gadodiamide and Gadobutrol

Luis Hummel,Thomas Frenzel,Janina Boyken,Hubertus Pietsch,Erdmann Seeliger

DOI: https://doi.org/10.1097/rli.0000000000001054

IF: 6.7

2024-01-06

Investigative Radiology

Abstract:In 2014, Kanda and colleagues 1 were the first to report abnormally increased signal intensity in the dentate nucleus and globus pallidus (GP) on unenhanced T1-weighted brain magnetic resonance images (MRIs) in patients with normal kidney function who had previously received repeated injections of the linear gadolinium-based contrast agents (GBCAs) gadodiamide or gadopentetate dimeglumine. The vast majority of studies corroborated the finding of T1 hyperintensities after intravenous administration of linear GBCAs, but not after macrocyclic GBCAs in clinical cohorts with different age, sex, medical (pre)conditions, and GBCA dosage regimen. 2–7

radiology, nuclear medicine & medical imaging
Gadolinium retention effect on macrophages — a potential cause of MRI contrast agent Dotarem toxicity

Marta Halasa,Ahmed Uosef,Henry V Ubelaker,Arijita Subuddhi,Krupa R Mysore,Jacek Z Kubiak,Rafik M Ghobrial,Jarek Wosik,Malgorzata Kloc,Henry V. Ubelaker,Krupa R. Mysore,Jacek Z. Kubiak,Rafik M. Ghobrial

DOI: https://doi.org/10.1007/s00441-024-03885-8

2024-04-17

Cell and Tissue Research

Abstract:Gadolinium is a component of the MRI contrast agent Dotarem. Although Dotarem is the least toxic among MRI contrasts used, gadolinium present in Dotarem accumulates for many years in various organs and tissues exerting toxic effects. We showed previously that gadolinium remains in macrophages for at least 7 days after exposure to Dotarem. However, very little is known about the effect of gadolinium retention on the immune cells such as macrophages. We studied the effect of 1-day and 7-day retention of gadolinium on various functions and molecular pathways of macrophages Gadolinium retention for 7 days decreased macrophage adhesion and motility and dysregulated the expression of adhesion and fibrotic pathway-related proteins such as Notch1 and its ligand Jagged1, adhesion/migration-related proteins PAK1 and Shp1, immune response-related transcription factors Smad3 and TCF19, and chemokines CXCL10 and CXCL13, and dysregulated the mRNA expression of fibrosis-related genes involved in extracellular matrix (ECM) synthesis, such as Col6a1 , Fibronectin , MMP9 , and MMP12 . It also completely (below a level of detection) shut down the transcription of anti-inflammatory M2 macrophage polarization marker the Arg-1 . Such changes, if they occur in MRI patients, can be potentially detrimental to the patient's immune system and immune response-related processes.

cell biology
Exceedingly small iron oxide nanoparticles as positive MRI contrast agents

He Wei,Oliver T. Bruns,Michael G. Kaul,Eric C. Hansen,Mariya Barch,Agata Wiśniowska,Ou Chen,Yue Chen,Nan Li,Satoshi Okada,Jose M. Cordero,Markus Heine,Christian T. Farrar,Daniel M. Montana,Gerhard Adam,Harald Ittrich,Alan Jasanoff,Peter Nielsen,Moungi G. Bawendi

DOI: https://doi.org/10.1073/pnas.1620145114

IF: 11.1

2017-02-13

Proceedings of the National Academy of Sciences

Abstract:Significance Gadolinium (Gd)-based contrast agents (GBCAs) are currently the mainstream clinical MRI contrast agents. Some GBCAs have shown a long-term toxicity—nephrogenic systemic fibrosis (NSF)—and Gd depositions in the brain. The NSF has triggered a Food and Drug Administration (FDA) black-box warning and a contraindication of some GBCAs. The finding of Gd depositions led to an ongoing FDA investigation to monitor their possible long-term adverse effects. Here, we present T 1 -weighted contrast-enhanced MR imaging and angiography using zwitterion-coated exceedingly small superparamagnetic iron oxide nanoparticles (ZES-SPIONs) in mice and rats. Renal clearance and biodistribution results further demonstrate that ZES-SPIONs are qualitatively different from previously reported SPIONs. This work may open up opportunities to develop exceedingly small SPIONs that show effective T 1 contrast as Gd-free alternatives to GBCAs.
Safe Use of Contrast Media: What the Radiologist Needs to Know

Katrina R Beckett,Andrew K Moriarity,Jessica M Langer

DOI: https://doi.org/10.1148/rg.2015150033

Radiographics

Abstract:Iodinated and gadolinium-based contrast media are used on a daily basis in most radiology practices. These agents often are essential to providing accurate diagnoses, and are nearly always safe and effective when administered correctly. However, reactions to contrast media do occur and can be life threatening. Therefore, it is critical for faculty and staff to know how reactions to contrast agents manifest and how to treat them promptly. The decline in renal function seen occasionally after intravenous administration of iodinated contrast agents is poorly understood and likely multifactorial, and its association with the contrast medium may be overemphasized. However, it is important that radiologists be aware of current understanding and strategies to decrease the incidence of renal dysfunction. Nephrogenic systemic fibrosis, a skin disease, is an adverse reaction related to use of some gadolinium-based contrast agents in patients with chronic renal failure. The types of gadolinium most often associated with this condition and the indications for withholding gadolinium are important and are discussed in this article. The use of enteric contrast agents and contrast agents during pregnancy and nursing are reviewed briefly. Current knowledge for safe use of contrast media and key concepts that all radiologists should know are summarized in this review.

[Simultaneous development of a bronchial cancer and a pulmonary tuberculosis: difficulty of the diagnosis].

Metabolomic Analysis of N-acetylcysteine Protection of Injury from Gadolinium-DTPA Contrast Agent in Rats with Chronic Renal Failure

Gadolinium-based contrast agents – what is the evidence for ‘gadolinium deposition disease’ and the use of chelation therapy?

Benefits and Detriments of Gadolinium from Medical Advances to Health and Ecological Risks

Biochemical Effects of Gadolinium Chloride in Rats Liver and Kidney Studied by 1H NMR Metabolomics

Toxicity of MRI and CT contrast agents

Toxicity Mechanisms of Gadolinium and Gadolinium-Based Contrast Agents—A Review

Gadolinium Deposition in the Liver and Brain in a Rat Model with Liver Fibrosis after Intravenous Administration of Gadoxetate Disodium

Gadolinium‐based Contrast Agents for Magnetic Resonance Cancer Imaging

Contrast Media-driven Anthropogenic Gadolinium: Knowns and Unknowns

Parallel Comparative Studies on Mouse Toxicity of Oxide Nanoparticle- and Gadolinium-Based T1 MRI Contrast Agents

Toxicological Risk Assessments of Iron Oxide Nanocluster- and Gadolinium-Based T1MRI Contrast Agents in Renal Failure Rats

Epidural anesthesia in a patient with hyperkalemic periodic paralysis undergoing orthopedic surgery

MRI Gadolinium‐Based Contrast Media: Meeting Radiological, Clinical, and Environmental Needs

Carbohydrate craving. Relationship between carbohydrate intake and disorders of mood.

A Contrast Examination of Proinflammatory Effects on Kidney Function for γ-Fe2O3 NP and Gadolinium Dimeglumine

Deposition of Gadolinium in the Central and Peripheral Nervous Systems and Its Effects on Sensory, Cognitive, and Athletic Implications after Multiple Injections of Gadolinium-Based Contrast Agents in Rats

Comprehensive Analysis of the Spatial Distribution of Gadolinium, Iron, Manganese, and Phosphorus in the Brain of Healthy Rats After High-Dose Administrations of Gadodiamide and Gadobutrol

Gadolinium retention effect on macrophages — a potential cause of MRI contrast agent Dotarem toxicity

Exceedingly small iron oxide nanoparticles as positive MRI contrast agents

Safe Use of Contrast Media: What the Radiologist Needs to Know